Amundi’s Lyell Immunopharma LYEL Stock Holding History

Amundi’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-211	Closed	-$13.7K	–	2096
2022 Q4	$13.7K	Buy	+211	New	+$21K	﹤0.01%	1828

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Amundi's LYEL Position: Q1 2023 in Review

Amundi sold out of Lyell Immunopharma (LYEL) in Q1 2023, closing a stake of 211 shares — an estimated $13.7K sold.

Amundi first reported a position in LYEL in Q4 2022 and held it in 1 quarter. The position peaked at $13.7K in Q4 2022. 99 funds tracked by Wall St. Rank hold LYEL as of Q1 2023.

Amundi reported no remaining Lyell Immunopharma position as of Q1 2023 after selling out during the quarter.
Amundi sold 211 Lyell Immunopharma shares in Q1 2023, an estimated $13.7K.
Amundi first reported a position in Lyell Immunopharma in Q4 2022 and held it in 1 quarter.
Amundi's Lyell Immunopharma position peaked at $13.7K in Q4 2022.
99 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2023.

Based on Amundi's 13F filing for Q1 2023, filed 15 May 2023.